Anzeige
Mehr »
Donnerstag, 27.08.2026 - Börsentäglich über 12.000 News
Jetzt darf dieser Small-Cap US-Kunden an die Crypto.com-Börse führen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
27.08.26 | 20:07
31,240 Euro
-0,86 % -0,270
Branche
Chemie
Aktienmarkt
Japan 225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
31,19031,41020:14
31,24031,40020:08

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
DiTakeda's Orzeyful secured Japan MHLW approval for narcolepsy type 112
MoKROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak7
15.08.Can Keros Therapeutics (KROS)'s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?26
13.08.Zealand sells its rights to Takeda's blood cancer drug for $100M ahead of FDA approval decision23
10.08.Silence brings the noise to Takeda with phase 2 blood cancer win30
06.08.Takeda approval ushers in new wave of sleep drugs26
06.08.Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful5
06.08.Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval7
06.08.Takeda nets first-in-class advantage on narcolepsy drug's FDA go-ahead4
06.08.Takeda's first-in-class narcolepsy drug claims FDA approval7
06.08.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer2
06.08.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::U.S. FDA APPROVES TAKEDA ORZEYFUL (OVEPOREXTON)7
30.07.Keros to receive $20 million milestone from Takeda partnership5
30.07.Keros Therapeutics, Inc.: Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda236LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...
► Artikel lesen
30.07.Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one26
30.07.Takeda Pharmaceutical Q1 Net Profit Slips From Higher Costs; Reaffirms FY26 Outlook452TOKYO (dpa-AFX) - On Thursday, Takeda Pharmaceutical Company Ltd. (TAK) reported decline in first quarter profit, dented by higher costs, despite higher revenues. Further, the company reiterated...
► Artikel lesen
30.07.Takeda Q1 FY2026 slides: three launches ahead as revenue dips18
30.07.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer5
30.07.TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::FIRST QUARTER RESULTS13
30.07.Takeda Pharmaceutical reports Q1 results21
Weiter >>
162 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1